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Abstract
Background: Patients with new onset constipation or presumed hemorrhoid bleeding frequently
require the use of both fiber supplements and diagnostic colonoscopy. We sought to determine
whether preliminary fiber supplementation would alter the tolerability or efficacy of a standard
bowel preparation for colonoscopy
Methods: A prospective, double blind, randomized trial was designed to compare a short course
of a psyllium-based supplement versus placebo prior to a colon lavage. Patients were given an
unlabeled canister of powder, and instructed to take 1 tablespoon with 8 oz of water bid for 4 days
before colonoscopy. A 4-liter polyethylene based glycol lavage was self-administered over 4 hours
on the day prior to colonoscopy. A questionnaire on pre-study bowel habits and side effects was
completed. Efficacy of the preparation was visually evaluated on a pre-determined scale.
Results: There were no significant differences between the two groups in gender, race, age, pre-
study stool frequency or consistency. Tolerability was equivalent but efficacy of the bowel
preparation was worse in the psyllium group compared to placebo (P < 0.05).
Conclusions: In non-constipated patients psyllium based fiber supplementation should not be
initiated in the few days prior to endoscopy using a polyethylene glycol preparation.
Background
Colorectal cancer is the second leading cause of cancer
mortality in the US with an estimated 150,000 new cases
expected to be diagnosed in 2003 [1]. The recognition that
prompt diagnosis and removal of neoplastic polyps is
associated with decreased colorectal cancer mortality has
stimulated more aggressive screening. Increasing public
awareness and the availability of reimbursement for
screening colonoscopy may further increase the number
of screening colonoscopies performed. In addition, the
typical Western diet is notable for a relative deficiency in
dietary fiber, and a high prevalence of colon disorders
including irritable bowel syndrome, diverticulosis (with
or without diverticulitis), neoplastic polyps, cancer and a
myriad of anal disorders. Many of the symptoms or signs
related to these disorders also prompt screening for color-
ectal cancer or other significant colonic pathology.
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Adequate bowel preparation is critical to colonoscopy, as
a poor preparation may obscure pathology or prevent full
colonoscopy. Rex at al. estimated that unsuccessful colon-
oscopy leads to second procedures in up to 20% of
patients [2]. Most colonoscopists advise the patient to
eschew fruits and vegetables for some period of time prior
to colonoscopy because large undigested fragments of
these foods may remain in the colon and obscure the
bowel. However, the need to avoid powdered fiber sup-
plements, which consist of much smaller particles, is less
clear. Indeed, dietary or supplemental fiber is an essential
element of colon health and bulk transit of stool. McRorie
described a new objective measure "Stool Viscosity Ratio",
a ratio of highest stool viscosity to lowest stool viscosity
[3]. This was useful in explaining the origin of High
Amplitude Propagating Contractions, motor activity of
the colon felt to be primarily responsible for cramping
pains when high volume luminal liquid meets solid stool.
Since cramping is felt to be a major component of discom-
fort during colon preparation [4], it was hypothesized that
pre-treating the colon with a stool-softening fiber supple-
ment could reduce cramping and improve tolerability.
More importantly, since many patients requiring colonos-
copy may also benefit from fiber supplementation, either
because of hemorrhoidal problems or constipation, we
sought to determine whether fiber supplementation in
the fiber-naïve patient might alter the quality of the bowel
preparation, either from direct mechanical effects of the
fiber on the stool or from changes in tolerability and com-
pliance with the preparation.
We therefore sought to determine whether starting fiber
supplementation prior to colonoscopy might affect the
tolerability or efficacy of a standard polyethylene glycol
based lavage preparation for colonoscopy. We established
a randomized double blind trial in which consenting
patients received either powdered psyllium or a placebo
control twice daily for four days prior to large volume pol-
yethylene glycol preparation and colonoscopy. We then
compared the discomfort produced by the preparation
and the adequacy of bowel preparation at colonoscopy in
these two groups of patients.
Methods
Patients
After approval by the Institutional Review Board of Wayne
State University, eligible patients were offered trial partic-
ipation. Patients were eligible if they were scheduled to
undergo elective colonoscopy for screening or symptom
evaluation and could comply with required procedures.
Patients were excluded for chronic laxative use, chronic
use of fiber supplements, swallowing difficulties, known
or suspected bowel obstruction, prior colon resection,
allergy to psyllium or aspartame, or diabetes.
Study design
Following informed consent, patients were entered into a
prospective, randomized, double blind trial of psyllium
powder (sugar-free Metamucil®, Procter & Gamble,
Mason, Ohio) versus placebo (Tang®, Kraft Foods, North-
field, Illinois) as an adjunct to bowel preparation for
colonoscopy. Patients were seen by the research pharma-
cist and randomized equally between the two groups
using pulled cards. Patients were assigned to either psyl-
lium or placebo, 1 heaping tablespoon BID with a full 8
ounces of water for four days prior to colonoscopy. The
fiber content in the psyllium arm was approximately 20
grams per day, based on 3.4 grams of fiber per teaspoon.
The patients were provided with an unlabeled canister,
which was returned to the pharmacy for weight determi-
nation on the day of colonoscopy. A low bulk fiber diet
was prescribed for the duration of the study. A study nurse
was in contact with patients over this time to improve
compliance and completion of the study. On the day prior
to colonoscopy each patient was advised to consume a
standard four-liter polyethylene glycol based electrolyte
solution (PEG-3350 & electrolytes for oral solution,
Colyte®, Schwarz Pharma, Milwaukee, Wisconsin) over 3–
4 hours. On the day of colonoscopy, each patient under-
went a structured interview that included questions rating
pre-preparation bowel habits such as frequency (bowel
movements per day or week), consistency (a visual analog
scale from 1–7, watery to hard and difficult to pass), and
the number of minutes per day spent attempting to defe-
cate. Compliance with the regimen (diet, PEG-3350, and
powder) was self-reported as a fraction from non-compli-
ant to fully compliant. Medication canisters were weighed
prior to distribution and upon return to further assess
compliance. Tolerability of the four-day regimen (first
hour of lavage, full volume of lavage, and overall tolera-
bility of the regimen) evaluating bloating, gas, cramping,
urgency, nausea and heartburn was assessed using a previ-
ously published visual analog scale from 0 (none) to 5
(extreme) [3]. During colonoscopy, a surgical endoscopist
not involved in the endoscopy itself observed the entire
procedure and assessed the quality of bowel preparation
based on the worst portion of the exam using a scale of 1–
7 to facilitate data analysis (Table 1). Subjective observa-
tions on the bowel preparation were permitted in addi-
tion to the overall score. Volume of irrigation was
recorded as part of the score. Patient, endoscopist, and
observer were all blinded to the study medication
throughout the study and the blind was only broken after
all patients had completed the research study.
Statistical analysis
A preliminary power calculation utilized quality of the
bowel preparation as the primary endpoint for this study,
since an improvement in tolerability would not be con-
sidered as important as a change in efficacy of theBMC Gastroenterology 2004, 4 http://www.biomedcentral.com/1471-230X/4/2
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preparation. We sought to find a difference in the mean
quality of bowel preparation (based upon our previously
established scale) of 1.0, and hypothesized based upon
previous pilot experience developing and validating the
scale that the standard deviation of this data would also
be 1.0. With a sample size of 20 in each group, this yielded
an estimated power of 0.869 for the study as designed,
which we considered acceptable. Validity of randomiza-
tion for age, gender, stool frequency, consistency, time
spent attempting to defecate, and compliance with the
regimen was assessed using Chi-square analysis for dis-
continuous variables or proportions and students T-test
assuming unequal variance for continuous variables. Dif-
ferences in tolerability between the regimen with the
active fiber supplement and that with the placebo were
assessed by comparing the mean score for each symptom
at each time point by two-tailed T-test assuming unequal
variance. Efficacy was compared using the two-tailed T-
test assuming unequal variance. Statistical significance
was established a priori at P < .05. Results for continuous
variables are presented as X ± SD.
Results
64 patients initially consented and enrolled in the study.
24 patients were subsequently excluded from being ana-
lyzed. Ten patients chose not to undergo colonoscopy
after initially consenting to the procedure. Eleven patients
withdrew from the study after receiving their assigned can-
ister and underwent colonoscopy without powder supple-
mentation. Two patients were excluded because they did
not consume at least 75% of the colyte solution, and one
patient was removed for self-prescribing a laxative during
preparation. All information leading to exclusion was
ascertained prior to colonoscopy. The 24 patients
excluded were equally divided between the two test pow-
ders (12 psyllium and 12 placebo). Of the 10 patients not
undergoing colonoscopy, 6 were initially randomized to
the placebo group and 4 to the psyllium group. Of the 11
patients withdrawing, 5 were initially randomized to psyl-
lium and 6 to the placebo arm.
This left 40 fully evaluable patients, with 20 allocated to
each of the two groups. Thirty-nine of 40 patients were
male, consistent with the Veterans Administration Hospi-
tal population. Mean age in the psyllium and placebo
groups was 60.4 ± 9.6 years and 61.4 ± 10.9 years respec-
tively. Eighty percent of the psyllium patients and 85 per-
cent of the placebo group had a stool frequency of "daily"
or more frequently. Stool consistency was self-reported on
the 1–7 scale as 4.3 ± 1.1 for psyllium and 4.0 ± .8 for the
placebo group. Self-reported time at stool for each bowel
movement for the psyllium group was 8.8 ± 7.8 minutes
and for placebo 7.1± 6.9 minutes. Median and modal val-
ues for time at stool were significantly lower than the
mean, but there was no difference between psyllium and
placebo. Median time was 5–6 minutes and the mode 2–
3 minutes indicating a skewed distribution secondary to
prolonged defecating times reported by a minority of
"readers". Compliance with a low fiber diet was described
as "mostly" (20%), or "completely" (75%) in both
groups. Self-reported compliance with powder consump-
tion in the psyllium group was "no missed doses" (70%)
"missed one dose" (20%), and "missed two doses"
(10%). Comparative compliance in the placebo group
was 75%, 15%, and 10% respectively. By canister weight,
the powder consumed in the psyllium group was 80.1 ±
26.7 grams with an expected consumption of 88 grams.
There were no significant differences between the psyl-
lium and placebo groups with respect to gender, race, pre-
preparation bowel frequency, stool consistency, time def-
ecating, or compliance with the prescribed regimen (diet,
PEG-3350, or powder).
No significant differences were found in tolerability of the
two regimens for bloating, gas, cramping, urgency, nau-
sea, or heartburn assessed during the first hour of PEG-
3350 lavage, full volume of PEG-3350 or overall. Scores
for each of the symptoms varied widely with a near zero
incidence of nausea or heartburn. Most patients reported
minimal to no discomfort, with only a mild sense of
bloating and urgency; however these were the only side
effects for which several patients recorded a score of 5
(extreme). Two of the 40 patients described extreme (5/5)
cramping with the full volume of lavage, but all other
patients reported minimal or no cramping (2 or less).
Table 1: Grading of Bowel Preparation
1. Clean mucosa ± occasional liquid stool
2. Clean mucosa with <100 cc liquid stool
3. Clean mucosa with 100–300 cc liquid stool
4. Clean mucosa with >300 liquid stool or small amounts of formed stool
5. Moderate amount of formed stool – mucosa still evaluable
6. Moderate to large amount of formed stool – mucosa not fully evaluable
7. Unable to reach cecum secondary to formed stool
8. Unable to reach cecum for technical reasons unrelated to the prep.BMC Gastroenterology 2004, 4 http://www.biomedcentral.com/1471-230X/4/2
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The cecum was reached in 18 of 20 in the psyllium group
and 19 of 20 in the placebo group. This difference was not
statistically significant. However, the quality of bowel
preparation was significantly worse in patients receiving
psyllium. The bowel preparation for the psyllium group
was scored as 3.8 ± 1.39 (X ± SD). In contrast, bowel prep-
arations of patients taking the placebo were scored as 2.6
± 1.4 (X ± SD). This difference was statistically significant
by T test assuming unequal variances. (N = 20, p = 0.009).
No attempt was made to independently score individual
anatomic segments of the colon. Review of subjective
comments beyond the bowel preparation scores by the
blinded observer after the double blind had been broken
were remarkable only for the observation that two
patients in the psyllium group were noted to have an unu-
sual fecal coating or "paste-like" appearance in the right
colon. This was not described in any patients in the pla-
cebo group.
Discussion
Colonoscopy remains the gold standard to evaluate the
colonic mucosa. Several pre-colonoscopy bowel prepara-
tion regimens exist, but none has emerged as clearly supe-
rior. In all these regimens, patients are generally asked to
avoid fruit and vegetable intake as much as possible for
some period of days prior to colonoscopy because large
undigested pieces of vegetable fiber could interfere with
complete visualization of the mucosa. The introduction of
a polyethylene glycol (PEG) based colon lavage in 1980
[5] has minimized the fluid and electrolyte problems
associated with potent hypertonic cathartics. However,
patients frequently find the large volume of liquid diffi-
cult to tolerate, leading to non-compliance and inade-
quate preparation. Many investigators have therefore
continued to study sodium phosphate preparations with
varying results [4,6-9]. Others have attempted to circum-
vent the volume problem by combining varying doses of
the stimulant laxative bisacodyl with a lower volume
PEG-based lavage [10].
Residual feces after poor bowel preparation may obscure
lesions or even prevent completion of the procedure.
Repeat bowel preparation and additional testing after
incomplete procedures places additional burdens upon
the patient and the health care system, while the cost of
missed lesions is obvious. Providing an effective and well-
tolerated bowel preparation is thus desirable.
This study attempted to improve tolerability and efficacy
of a standard PEG preparation with a short preliminary
course of a psyllium-based powdered fiber. This study
failed to demonstrate any improvement. In fact, psyllium
impaired bowel preparation. Several possibilities exist for
decreased efficacy, including continuing fiber supplemen-
tation on the day of lavage, the adhesion of small particles
of fiber and stool to the mucosa or non-compliance with
adequate water intake, which was not measured. Whether
these findings are relevant for chronically constipated
patients who are already dependent on chronic fiber sup-
plementation cannot be answered by this study.
In this group of non-constipated patients, who generally
self-rated their stool consistency as midway between liq-
uid and hard, moved their bowels daily or more often,
and spent a median time at defecating of 5–6 minutes, the
cramping pains associated with high pressure contrac-
tions as hypothesized by McRorie [3] did not seem highly
prevalent during a PEG lavage preparation and were not
influenced by use of psyllium powder. Urgency during the
4-hour lavage phase was the most notable side effect of
the bowel preparation but was expected to some extent by
all patients and thus may have been under-reported.
Bloating was the second most frequent side effect and gen-
erally mild.
The use of a dietary powdered fiber preparation is well
established for a myriad of colorectal problems, including
constipation, anal fissures, symptomatic hemorrhoids,
and recurrent diverticulitis. Fiber may also facilitate cho-
lesterol control. Colonoscopy requires a well-prepared
colon to reduce the need for premature repeat testing or
the requirement for additional diagnostic tests. This study
suggests that powdered fiber supplementation should not
be initiated within a few days before a colon lavage prep-
aration for colonoscopy. Although fiber supplementation
is clearly effective for hemorrhoidal disease, patients pre-
senting with presumed hemorrhoidal bleeding should
either receive colonoscopy first or the endoscopist may
wish to consider stopping the fiber supplement several
days prior to colonoscopy if a PEG-based preparation is to
be used. The impact of fiber on a sodium phosphate prep-
aration is unknown, but might be speculated to be
similar. Patients suffering from significant constipation
may represent a distinct cohort requiring individualized
treatment.
Nearly 37% of initially randomized patients failed to
complete the study. Patients withdrawing after initial con-
sent were not pursued or formally questioned regarding
their decision to withdraw since the primary endpoint of
the study was efficacy of bowel preparation and not toler-
ability. However, the number of patients failing to com-
plete the study was equally distributed between the two
groups, suggesting that the side effects of either medica-
tion were probably not responsible for self-removal from
the study. The "no show" or cancellation rate for colonos-
copy at the study facility outside of research is approxi-
mately 25% from all causes. In this limited study, patients
were not stratified by their indication for endoscopy.
However, others have not found this to be an independ-BMC Gastroenterology 2004, 4 http://www.biomedcentral.com/1471-230X/4/2
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ent variable for efficacy in bowel preparation [10]. A uni-
formly accepted scale for both tolerability and efficacy
would enhance comparison between divergent strategies.
Conclusions
Psyllium based fiber supplementation does not signifi-
cantly improve tolerability of a lavage based preparation
for colonoscopy and when provided within several days
of colonoscopy may impair visualization. At least in non-
constipated patients fiber supplementation should be dis-
continued prior to a lavage based preparation for colonos-
copy, and patients who require both colonoscopy and a
prescription for fiber supplementation should receive
colonoscopy prior to starting fiber supplements.
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Table 2: Demographics of Study Population
Psyllium Placebo Significance
Age 60.4 ± 9.6 61.4 ± 10.9 Ns
Stool Consistency 4.3 ± 1.1 4.0 ± .8 ns
Stool Frequency ns
Weekly 01
Every other day 21
Occ. skip days 21
Daily 12 10
Twice daily 36
More than bid 11
Compliance
With diet ns
Complete 15/20 15/20
Partial 4/20 4/20
Not Compliant 1/20 1/20
With powder ns
Complete 14/20 15/20
Missed 1 dose 4/20 3/20
Missed 2 doses 2/20 2/20
Table 3: Efficacy and Tolerability of Bowel Preparation
Psyllium Placebo Significance
Cecum 18 /20 19 /20 ns
Quality 3.8 ± 1.39 2.68 ± 1.4 P=.009
Tolerability*
Bloating 1.75 ± 1.6 1.1 ± 1.3 ns
Gas 1.7 ± 1.45 1.1 ± 1.0 ns
Cramping 0.5 ± 1.5 0.35 ± .81 ns
Urgency 2.4 ± 1.8 2.6 ± 1.53 ns
Nausea 0.15 ± 0.6 0.1 ± .44 ns
Heartburn 0 ± 0 0.25 ± .78 ns
* Worst mean score (0–5) for any of three time periods, (First Hour, Full Lavage, Overall)Publish with BioMed Central    and   every 
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